Sanerna SGB-9768 Interim Data Show Steep UPCR Declines Across Three Kidney Disease Cohorts

Sanerna presented interim results from a mid-stage study of SGB-9768 at ASN Kidney Week, showing reductions in twenty-four-hour urine protein-to-creatinine ratio between roughly fifty-nine percent and seventy-four percent from baseline across three patient cohorts.